Results from Phase 1 Multiple-Dose Study of PT00114

Core Insights - Protagenic Therapeutics Inc. has reported positive topline safety results from its Phase 1 Multiple Dose study of PT00114, a synthetic analogue aimed at addressing stress-related neuropsychiatric conditions [1] Company Summary - Protagenic Therapeutics Inc. is focused on developing therapeutics that target the biology of chronic stress and its psychiatric and neurologic effects [1] - PT00114 is designed to restore homeostasis following prolonged exposure to stress, indicating its potential as a first-in-class treatment [1] Industry Context - The advancement into Phase 2 of PT00114 suggests a growing interest in addressing neuropsychiatric conditions linked to chronic stress, highlighting a potential market opportunity for innovative therapies in this area [1]